35853-44-2

Basic information

• Product Name: 2,5-bis(trifluoromethyl)quinolin-4-ol
• Synonyms: 2,5-bis(trifluoromethyl)quinolin-4-ol
• CAS NO: 35853-44-2
• Molecular Formula: C11H5F6NO
• Molecular Weight: 281.1539192
• Mol File: 35853-44-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,5-bis(trifluoromethyl)quinolin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-bis(trifluoromethyl)quinolin-4-ol(35853-44-2)
• EPA Substance Registry System: 2,5-bis(trifluoromethyl)quinolin-4-ol(35853-44-2)

Safety Data

• Hazardous Substances Data: 35853-44-2(Hazardous Substances Data)

Usage

General Description

2,5-bis(trifluoromethyl)quinolin-4-ol is a chemical compound with the molecular formula C15H8F6NO. It is a derivative of quinolin-4-ol, and its structure includes two trifluoromethyl groups attached to the 2 and 5 positions of the quinoline ring. 2,5-bis(trifluoromethyl)quinolin-4-ol is known for its high electronegativity due to the presence of the fluorine atoms, which makes it useful in various chemical reactions and as a building block in the synthesis of other compounds. It also exhibits potential biological activities, making it of interest in pharmaceutical research. The compound may have uses in the development of drugs, agrochemicals, and materials science.

Upstream product

• 98-16-8 3-trifluoromethylaniline 
• 372-31-6 ethyl 4,4,4-trifluoroacetoacetate 

Relevant articles and documents

Structure-Activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating mycobacterium tuberculosis

Tuberculosis (TB) remains as a global pandemic that is aggravated by a lack of health care, the spread of HIV, and the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDRTB) strains. New anti-TB drugs are urgently required to shorten the long 6-12 month treatment regimen and to battle drug-resistant Mtb strains. We have identified several potent quinoline-based anti-TB compounds, bearing an isoxazole containing side-chain. The most potent compounds, 7g and 13, exhibited submicromolar activity against the replicating bacteria (R-TB), with minimum inhibitory concentrations (MICs) of 0.77 and 0.95 μM, respectively. In general, these compounds also had micromolar activity against the nonreplicating persistent bacteria (NRP-TB) and did not show toxicity on Vero cells up to 128 μM concentration. Compounds 7g and 13 were shown to retain their anti-TB activity against rifampin, isoniazid, and streptomycin resistant Mtb strains. The results suggest that quinoline-isoxazole-based anti-TB compounds are promising leads for new TB drug development.